SCHEMBL5060340

SCHEMBL5060340

CNc1ncc2cc(-c3cccc(NC(=O)Nc4cnc(C(C)(C)C)nc4-c4cnoc4)c3)c(=O)n(C)c2n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.43
FGFR1 P11362 3/20 0.43
EGFR P00533 2/20 0.43
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42
ABL1 P00519 4/20 0.41
PDGFRB P09619 2/20 0.41
PDGFRA P16234 2/20 0.41
MAPK14 Q16539 2/20 0.41
STK4 Q13043 1/20 0.39
STK3 Q13188 1/20 0.39
SIK2 Q9H0K1 1/20 0.39
STK26 Q9P289 1/20 0.39
STK24 Q9Y6E0 1/20 0.39
WEE1 P30291 4/20 0.39
RIPK2 O43353 1/20 0.39
ACVR1 Q04771 1/20 0.39
FGFR4 P22455 2/20 0.39
SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4277858 0.91 SRC (0.47) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5056532 0.88 RAF1 (0.47) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5054961 0.88 SRC (0.44) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5062562 0.88 FGFR1 (0.46) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5054636 0.87 SRC (0.43) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5052259 0.85 SRC (0.42) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5056477 0.83 SRC (0.45) SRCFGFR1EGFRRAF1BRAF
SCHEMBL4274689 0.80 BRAF (0.49) SRCFGFR1EGFRRAF1BRAF
SCHEMBL5054627 0.80 BRAF (0.43) SRCRAF1BRAFABL1MAPK14
SCHEMBL5060234 0.78 KDR (0.34) SRCFGFR1EGFRRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 SRC 69/4885FGFR1 184/4885EGFR 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.